Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and

docum	ents given to ASX become ASX's propert	y and may be made public.
Introduc 04/03/13		8, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12,
Name	of entity	
LifeH	Iealthcare Group Limited	
ABN		
72 16	6 525 186	
Part	the entity) give ASX the followin 1 - All issues ust complete the relevant sections (attac	
1	+Class of +securities issued or to	Ontions even fully naid andinamy shares
1	be issued	Options over fully paid ordinary shares ("Options").
		The Options are not quoted on the ASX.
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	158,200 options.
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Exercise price \$2.28 As per Annexure "A" to the Explanatory Memorandum accompanying the Notice of Annual General Meeting, lodged with the ASX on 25 September 2014.

Do the *securities rank equally Any shares resulting from the exercise of 4 in all respects from the +issue Options which vest pursuant to the date with an existing +class of LifeHealthcare Group Limited Employee quoted +securities? Option Plan ("LEOP") will rank equally in all respects with existing ordinary shares. If the additional +securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Issue price or consideration Nil. 5 The Options are granted for the purposes of Purpose of the issue (If issued as consideration for the LEOP. the acquisition of assets, clearly identify those assets) Is the entity an +eligible entity 6a No that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i The date the security holder 6b N/A resolution under rule 7.1A was passed Number of *securities issued | N/A 6c without security holder approval under rule 7.1 Number of +securities issued N/A 6d with security holder approval under rule 7.1A

⁺ See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A	
7	*Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	28 October 2014	
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	Number 42,500,000	+Class Fully paid ordinary shares
		Number	+Class

9	Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)	1,189,295 (Note: the balance of Options is affected by and may be varied by a number of events including the lapse of Options, or Options being forfeited)	Options		
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	No change.			
Part :	Part 2 - Pro rata issue				
11	Is security holder approval required?				
12	Is the issue renounceable or non-renounceable?				
13	Ratio in which the *securities will be offered				
14	⁺ Class of ⁺ securities to which the offer relates				
15	⁺ Record date to determine entitlements				
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?				
17	Policy for deciding entitlements in relation to fractions				
18	Names of countries in which the entity has security holders who will not be sent new offer documents				
	Note: Security holders must be told how their entitlements are to be dealt with.				
	Cross reference: rule 7.7.				
19	Closing date for receipt of acceptances or renunciations				

⁺ See chapter 19 for defined terms.

30	Names of any underwriters	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
32	How do security holders dispose of their entitlements (except by	

	sale t	hrough a broker)?	
33	⁺ Issue	e date	
		Quotation of securitie	
34	Type (tick	of *securities one)	
(a)		⁺ Securities described in Part	1
(b)		All other *securities	
	Example: restricted securities at the end of the escrowed period, partly paid securities that become fully pemployee incentive share securities when restriction ends, securities issued on expiry or conversion of converse		
Entit	ies tha	t have ticked box 34(a)	
Addi	tional	securities forming a new	class of securities
Tick to		e you are providing the informat	ion or
35			securities, the names of the 20 largest holders of the he number and percentage of additional *securities
36			securities, a distribution schedule of the additional umber of holders in the categories
		1 - 1,000	
		1,001 - 5,000 5,001 - 10,000	
		10,001 - 100,000 100,001 and over	
37		A copy of any trust deed for	the additional ⁺ securities
Entit	ies tha	t have ticked box 34(b)	
38		ber of *securities for which tation is sought	
39	⁺ Class of ⁺ securities for which quotation is sought		

⁺ See chapter 19 for defined terms.

40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not		
	 rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Nearth or	+Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	Number	+Class

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Date: 29 October 2014

Print name: David Wiggins, Company Secretary

~. 1 wgg -.

== == == ==

⁺ See chapter 19 for defined terms.